Last reviewed · How we verify

Laboratorios Richmond S.A.C.I.F. — Portfolio Competitive Intelligence Brief

Laboratorios Richmond S.A.C.I.F. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Treatment with nifedipine Treatment with nifedipine phase 3 Calcium channel blocker L-type calcium channels Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Addpharma Inc. · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Bioprojet · 1 shared drug class
  4. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  5. Bristol-Myers Squibb · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Handok Inc. · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Laboratorios Richmond S.A.C.I.F.:

Cite this brief

Drug Landscape (2026). Laboratorios Richmond S.A.C.I.F. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laboratorios-richmond-s-a-c-i-f. Accessed 2026-05-17.

Related